A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
2009 · Molecular Therapy · 265 citations
https://doi.org/10.1038/mt.2009.262
N
Neil Senzer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
242
Papers
13.1K
Citations
50
h-index
124
i10-index
Neil Senzer is an academic researcher from Mary Crowley Cancer Research Center. The author has contributed to research in topics: Cancer Research and Treatments & Virus-based gene therapy research & CAR-T cell therapy research. The author has an h-index of 50, co-authored 206 publications.
Papers by this author
worksThree-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
2016 · Molecular Therapy · 94 citations
https://doi.org/10.1038/mt.2016.86
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
2022 · Communications Medicine · 13 citations
https://doi.org/10.1038/s43856-022-00163-y
Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]
2021 · Gynecologic Oncology Reports · 3 citations
https://doi.org/10.1016/j.gore.2021.100740
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat